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Abstract We present a space- and phenotype-structured model of selection dy-
namics between cancer cells within a solid tumour. In the framework of this model,
we combine formal analyses with numerical simulations to investigate in silico the
role played by the spatial distribution of oxygen and therapeutic agents in me-
diating phenotypic selection of cancer cells. Numerical simulations are performed
on the 3D geometry of an in vivo human hepatic tumour, which was imaged us-
ing computerised tomography. Our modelling extends our previous work in the
area through the inclusion of multiple therapeutic agents, one that is cytostatic,
whilst the other is cytotoxic. In agreement with our previous work, the results show
that spatial inhomogeneities in oxygen and therapeutic agent concentrations, which
emerge spontaneously in solid tumours, can promote the creation of distinct local
niches and lead to the selection of different phenotypic variants within the same
tumour. A novel conclusion we infer from the simulations and analysis is that, for
the same total dose, therapeutic protocols based on a combination of cytotoxic and
cytostatic agents can be more effective than therapeutic protocols relying solely on
cytotoxic agents in reducing the number of viable cancer cells.
1 Introduction
In this work, we extend a space- and phenotype-structured model of selection
dynamics in a solid tumour that we proposed in [4,5]. Our model consists of
a nonlinear integro-differential equation (IDE) for the spatiotemporal evol-
ution of the phenotypic distribution of cancer cells coupled to a system of
nonlinear partial differential equations (PDEs) for the dynamics of abiotic
factors. A novel feature of this work, over [4], is that we consider multiple
spatially distributed therapeutic agents. Through the coupling of formal ana-
lyses and numerical simulations, we show that spatial variations in abiotic
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factors promote the formation of local niches and lead to the selection of dif-
ferent phenotypic variants, in agreement with the viewpoint of cancer as an
eco-evolutionary process [6]. The modelling carried out in the present work
allows us to consider optimisation of treatment protocols. In particular, our
results suggest that, for the same total dose, therapeutic protocols based on
the delivery of cytotoxic drugs in combination with cytostatic agents can be
more effective than therapeutic protocols relying solely on cytotoxic drugs in
reducing the number of viable cancer cells.
2 Model description
We identify the tumour geometry with a spatial domain Ω ⊂ R3. At any
time instant t ≥ 0, we characterise the state of each cancer cell in the tumour
by means of a pair (x, y) ∈ Ω × [0, 1]. The vector x ∈ Ω identifies the
spatial position of the cell and the scalar variable y ∈ [0, 1] ⊂ R stands
for the normalised expression level of a hypoxia-responsive gene [8]. Cells
within the tumour proliferate and die due to competition for limited space.
Moreover, both a cytotoxic drug, which acts by increasing the cell death
rate, and a cytostatic drug, which acts by reducing the cell proliferation rate,
can be administered. We assume increasing values of the phenotypic state
y to be correlated with a progressive switch towards a hypoxic phenotype
which, in turn, implies a progressive reduction in the proliferation rate [1].
Additionally, given that cytotoxic agents target mostly rapidly proliferating
cells, we assume that higher values of the phenotypic state y correspond with
higher levels of resistance to the cytotoxic drug [3].
Given the local population density n(t,x, y), we compute the cell density
and the mean cell phenotypic state at time t and position x as follows
ρ(t,x) =
∫ 1
0
n(t,x, y) dy and µ(t,x) =
1
ρ(t,x)
∫ 1
0
y n(t,x, y) dy. (1)
Finally, we introduce the functions s(t,x) ≥ 0, c1(t,x) ≥ 0 and c2(t,x) ≥ 0 to
model the local concentration of oxygen, cytotoxic drug and cytostatic drug
at position x and time t, respectively.
2.1 Dynamics of cancer cells
The dynamics of the local population density n(t,x, y) is governed by the
following nonlinear IDE
∂n
∂t
(t,x, y) = R
(
y, ρ(t,x), s(t,x), c1(t,x), c2(t,x)
)
n(t,x, y). (2)
In Eq. (2), the functional R
(
y, ρ, s, c1, c2
)
represents the fitness of cells in
phenotypic state y at position x and time t (i.e. the fitness landscape of
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the tumour), given the local environmental conditions determined by the cell
density ρ(t,x) and the concentrations of abiotic factors s(t,x), c1(t,x) and
c2(t,x). We define the fitness landscape of the tumour as
R
(
y, ρ, s, c1, c2
)
= f(y)︸︷︷︸
proliferation
in hypoxic conditions
+ r(y, s)
(
1− k2(c2)
)︸ ︷︷ ︸
proliferation
in oxygenated environments
− k1(y, c1)︸ ︷︷ ︸
death due to
cytotoxic drug
− d ρ(t,x).︸ ︷︷ ︸
death due to
competition for space
(3)
Building upon the considerations and the modelling strategies presented in
[4], we introduce the following definitions:
f(y) = ζ
[
1− (1− y)2
]
, r(y, s) = γs
s(t,x)
αs + s(t,x)
(
1− y2), (4)
k1(y, c1) = γc1
c1(t,x)
αc1 + c1(t,x)
(1− y)2, k2(c2) = γc2
c2(t,x)
αc2 + c2(t,x)
. (5)
The biological meaning of the different parameters are summarised in Table
1. The function 0 ≤ k2(c2) ≤ 1 measures the percentage reduction in the
proliferation rate of cancer cells caused by the cytostatic drug. Since the
efficacy of many cytostatic drugs is directly linked with adequate oxygen
tension [2], we make the prima facie assumption that the cytostatic drug
reduces the proliferation rate in oxygenated environments, whereas it does
not affect the proliferation rate under hypoxic conditions. For this reason, the
term f(y) is not multiplied by the factor
(
1− k2(c2)
)
. Moreover, we assume
the function k2 to be increasing in the drug dose c2. A detailed discussion of
the biological assumptions that underlie the definitions of the other functions
can be found in [4].
2.2 Dynamics of abiotic factors
The abiotic factors diffuse in space, decay over time and are consumed by
cells. We note that the dynamics of abiotic factors is faster than cellular
proliferation and death [9]. From a mathematical viewpoint, this means that
we can assume oxygen and the drugs to be in quasi-stationary equilibrium.
In this setting, the dynamics of the functions s(t,x), c1(t,x) and c2(t,x) are
described by the following elliptic PDEs which are coupled to the IDE (2)
βs∆s(t,x) = ηs
∫ 1
0
r
(
y, s
)
n(t,x, y) dy + λs s(t,x), (6)
βc1 ∆c1(t,x) = ηc1
∫ 1
0
k1
(
y, c1
)
n(t,x, y) dy + λc1 c1(t,x), (7)
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and
βc2 ∆c2(t,x) = ηc2
∫ 1
0
k2
(
c2
)
n(t,x, y) dy + λc2 c2(t,x). (8)
The biological meanings of the different parameters are summarised in Table
1 and further details can be found in [4]. Concentrating on the biological
scenario whereby the tumour is avascular and the concentrations of abiotic
factors in the medium surrounding the tumour are constant in time, we choose
the following boundary conditions for equations (6)-(8)
s(·,x) = S(x), c1(·,x) = C1(x) and c2(·,x) = C2(x) ∀x ∈ ∂Ω. (9)
3 Formal analysis of phenotypic selection
We denote the local cell density and the dominant phenotypic state (i.e.
the phenotypic state y that maximises the cellular fitness at position x) at
equilibrium as ρ(x) and y(x), respectively. Moreover, we denote the steady-
state distributions of abiotic factors as s(x), c1(x) and c2(x). By means of
the formal arguments used in [4], one finds
ρ(x) =
1
d
As,c2(x)−Ac1(x) +
(
ζ +Ac1(x)
)2
ζ +As,c2(x) +Ac1(x)
 (10)
and
y(x) =
ζ +Ac1(x)
ζ +As,c2(x) +Ac1(x)
, (11)
where
As,c2(x) = γs (1− k2(c2))
s(x)
αs + s(x)
and Ac1(x) = γc1
c1(x)
αc1 + c1(x)
.
Such formal results are consistent with the asymptotic results presented in
[7].
The expressions given by equations (10) and (11) demonstrate that the
local cell density ρ and the dominant phenotypic state y at a certain position
are determined by the concentrations of oxygen s, cytotoxic drug c1 and
cytostatic agent c2 at the same position. This is illustrated by the heat-maps
in Figure 1, which relate to the parameter values given in Table 1 and
c1 = K Ctot, c2 = (1−K)Ctot, K ∈ [0, 1]. (12)
The heat-maps display the values of ρ¯ and y¯ as functions of the parameter K
in Eq.(12) and the oxygen concentration s¯. We observe that, for sufficiently
high oxygen levels, the local cell density is minimised for values of K between
0.4 and 0.5, which corresponds to the situation whereby the cytotoxic drug
and the cytostatic agent are used in combination.
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Figure1: Heat-maps showing the local cell density ρ¯ and dominant phenotypic state
y¯ at equilibrium as functions of the parameter K [cf. Eq.(12)] and the local con-
centration of oxygen s¯. For sufficiently high oxygen levels, the local cell density is
minimised for values of K between 0.4 and 0.5, which corresponds to the situation
whereby the cytotoxic drug and the cytostatic agent are used in combination.
4 Numerical solutions
In this section we report on simulations of the model system (2), (6), (7) and
(8). For the spatial domain Ω we consider a tetrahedral discretisation of the
real geometry of a human hepatic tumour obtained from the 3D-IRCADb-
01 database (http://www.ircad.fr/). We make use of the following boundary
conditions for s, c1 and c2:
S(x) = S0 ∀x ∈ ∂Ω
and
C1(x) = K Ctot, C2(x) = (1−K)Ctot ∀x ∈ ∂Ω with K ∈ [0, 1]. (13)
The parameter Ctot measures the total delivered drug dose. To carry out
numerical simulations, we tune the value of the parameter K and we use the
values given in Table 1 for the other parameters of the model. Further details
on the tumour geometry and the model parametrisation can be found in [4].
For the elliptic PDEs, we use a P1 finite element method and treat the
nonlinear terms explicitly using the values from the previous time-step. For
the IDE, we use an IMEX Euler method in which the nonlinear terms are
treated explicitly. The mesh that we employ has 9932 DOFs and the time-
step we use correspond to 1 × 103 with a final time of 5 × 106, by which
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Table1: Nondimensionalised parameter values
Parameter Biological meaning Value
αc1 Michaelis-Menten constant of cytotoxic drug 0.2
αc2 Michaelis-Menten constant of cytostatic drug 10
−2
αs Michaelis-Menten constant of oxygen 0.2344
βc1 , βc2 Diffusion coefficients of cytotoxic and cytostatic drug 5
βs Diffusion coefficient of oxygen 20
γc1 Maximum cell death rate due to cytotoxic drug 1.8× 10−4
γc2 Maximum percentage reduction in cell proliferation rate due to cytostatic drug 0.8
γs Maximum cell proliferation rate in oxygenated environments 1.5× 10−5
ζ Maximum cell proliferation rate under hypoxic conditions 1× 10−6
d Rate of cell death due to competition for space 2× 10−5
ηc1 , ηc2 Scaling factors for cell consumption of the drugs 400
ηs Scaling factor for cell consumption of oxygen 3125.2
λc Decay rate of cytotoxic drug 0.1
λs Decay rate of oxygen 0.3
Ctot Total drug dose delivered 0.01
S0 Oxygen concentration in the surrounding environment 1
time the numerical solutions are at steady state values in all the cases under
consideration. The numerical method employed is detailed in [4].
Figure 2 summarises the numerical solutions at equilibrium for K = 0.6
[cf. Eq.(13)]. We show a slice through the tumour in order to visualise the
interior. We also post-process the computed values of Sh, C1,h and C2,h to
evaluate the corresponding dominant phenotypic state y¯ and the local cell
density ρ¯ according to Eqs.(10)-(11), which we compare with the computed
mean phenotypic state µh and local cell density ρh. There is an excellent
agreement between the numerical solutions at equilibrium and the predictions
of our formal analyses. As the qualitative features of the numerical solutions
for the other values of K are similar to those of the numerical solutions
obtained for K = 0.6, we do not display the equilibrium spatial distributions
for other values of K. However, in order to illustrate the variation in cell
density and phenotypic state at equilibrium as we change K, in Figure 3
we report on the computed total cell number and mean phenotypic state at
equilibrium in the tumour and on the tumour surface. The total number of
cells and the surface cell number at equilibrium are minimised for K ≈ 0.8
and K ≈ 0.4, respectively. We note that this agrees with the results of the
formal analysis illustrated by the heat-map in the left panel of Figure 1 as the
concentrations of therapeutic factors and oxygen correspond to those used to
make the plots of Figure 1 only at the boundary of the tumour.
Our results suggest that therapeutic protocols based on the delivery of
lower doses of cytotoxic drugs in combination with cytostatic agents may be
more effective than therapeutic protocols relying solely on higher doses of
cytotoxic drugs in reducing the number of viable cancer cells.
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Figure2: Upper row: computed equilibrium distributions of oxygen (Sh), cytotoxic
drug (C1h) and cytostatic drug (C2h) for K = 0.6. Lower row: computed mean
phenotypic state (µh), predicted dominant trait (y¯), computed (ρh) and predicted
(ρ¯) local cell density at equilibrium for K = 0.6. The results of the formal analysis
agree with the results of numerical simulations.
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Figure3: Reading from left to right, computed total cell number, surface cell num-
ber, mean phenotypic state over the tumour and surface mean phenotypic state at
equilibrium for different values of the parameter K. The total cell number over the
tumour is minimised amongst the considered values by taking K ≈ 0.8, whilst the
surface cell number is minimised for K ≈ 0.4.
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